About
Klaas P. Zuideveld is a biotech executive focused on drug development, translational strategy, and clinical execution. TECregen announced on January 29, 2026 that he had been appointed Chief Executive Officer to lead its thymus regeneration platform into clinical development. Earlier official Versameb materials show he joined as Chief Development Officer in May 2020 and was appointed CEO in January 2021; his prior industry experience includes Roche and Caris Life Sciences, and advisory or operating work with multiple biotech companies.
Areas of interest
biotechdrug developmentclinical developmentRNA therapeuticsimmunologyoncologyprecision medicinelongevity